The aim of this study is to evaluate the role of cognitive disorders and quality of life in patients with CIS, considered as high risk to develop an MS, treated with interferon Beta. This prospective observational study will include 120 patients, all treated and evaluated annually with neurological extensive examination, ophthalmologic screening (OCT, OF, VEP, VF), auto questionnaire about fatigue (musicol, ELIF), quality of life (SEP-59), and conventional MRI.
Study Type
OBSERVATIONAL
Enrollment
37
CHU de Bordeaux - Hôpital Pellegrin
Bordeaux, France
University hospital of Côte de Nacre
Caen, France
Hôpital Gabriel Montpied
Clermont-Ferrand, France
Clinical exams performed at Baseline and every year during 3 years Neurological examination: relapses recording and EDSS. Quality of life: SEP-59, MusiQOL. Neuropsychological screening
Time frame: 3 years
Fatigue test: MS Fatigue, MRI (T1 gadolinium, T2, sagittale T1, acquisition volumique 3D T1), Optical coherence tomography (OCT)
Time frame: 3 years
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Hôpital Général de DIJON
Dijon, France
Hôpital Roger Salengro
Lille, France
Hôpital de Saint Philibert
Lomme, France
Centre Hospitalier de la Timone
Marseille, France
Hôpital Gui de Chauliac
Montpellier, France
CHU de Nancy
Nancy, France
CHU de Nantes
Nantes, France
...and 7 more locations